ALV
0.038
65.2%
WLD
0.013
-53.6%
RLG
0.004
33.3%
LNU
0.001
-50%
DEV
0.145
26.1%
NTM
0.002
-33.3%
BSX
0.05
25%
ECS
0.005
-28.6%
ROC
0.155
24%
NSM
0.027
-27%
PTX
0.059
22.9%
CCO
0.003
-25%
M4M
0.006
20%
AQX
0.004
-20%
CYC
0.795
19.5%
PGY
0.004
-20%
AGY
0.074
19.4%
EDE
0.042
-19.2%
NYR
0.69
19%
KRR
0.013
-18.8%
WJL
0.885
17.2%
AN1
0.005
-16.7%
AUZ
0.014
16.7%
EVE
0.022
-15.4%
AX8
0.007
16.7%
NC1
0.11
-15.4%
IMI
0.014
16.7%
DRO
2.08
-15.1%
MML
0.035
16.7%
VBS
0.17
-15%
XPN
0.014
16.7%
HHR
0.006
-14.3%
AGC
0.195
14.7%
IVG
0.03
-14.3%
ALY
0.008
14.3%
OVT
0.006
-14.3%
W2V
0.008
14.3%
CF1
0.022
-12%
GML
0.083
12.2%
FLN
0.225
-11.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts